Mirum Pharmaceuticals (MIRM) Stock Statistics & Valuation Metrics

Mirum Pharmaceuticals has a market cap or net worth of $2.28B. The enterprise value is ―.

Mirum Pharmaceuticals has 49,534,710 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mirum Pharmaceuticals’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -16.24%.

The current PE Ratio of Mirum Pharmaceuticals is -22.34. Mirum Pharmaceuticals’s PEG ratio is -2.22.

In the last 12 months, Mirum Pharmaceuticals had revenue of 336.89M and earned -87.94M in profits. Earnings per share was -1.85.

In the last 12 months, operating cash flow was 10.32M and capital expenditures -10.99M, giving a free cash flow of 9.33M billion.

Mirum Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Mirum Pharmaceuticals upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Mirum Pharmaceuticals as a current ratio of 3.10, with Debt / Equity ratio of 140.83%

In the past 12 months, Mirum Pharmaceuticals has paid 1.03M in taxes.

Mirum Pharmaceuticals EV to EBITDA ratio is -42.07, with an EV/FCF ratio of 220.78.

Mirum Pharmaceuticals has $280.31M in cash and marketable securities with $317.76M in debt, giving a net cash position of $37.45M billion.

Gross margin is 75.77%, with operating margin of -26.00%, and net profit margin of -26.10%.

The average price target for Mirum Pharmaceuticals is $69.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy